<DOC>
	<DOCNO>NCT00150345</DOCNO>
	<brief_summary>A well-known side-effect cytostatics ( drug malignancy ) decrease number white blood cell , especially so-called neutrophil granulocyte , important defense infection . Hence decrease ( call `` neutropenia '' ) lead predisposition infection . Since infection neutropenia dangerous , patient treat antibiotic first sign infection ( usually fever ) . If antibiotic ( drug bacteria ) lead normalization body temperature within four day , drug fungi add . In IDEA study , one half patient receive antifungal drug voriconazole ( usual ) case antibiotic alone lead normalization body temperature ( current standard care ) . The half patient receive voriconazole immediately onset fever ( concomitantly antibiotic ) . The research question , whether `` early-treatment '' group few manifest fungal infection observe `` late-treatment '' group .</brief_summary>
	<brief_title>Immediate v . Deferred Empirical Antifungal Treatment With Voriconazole In Neutropenic Patients</brief_title>
	<detailed_description />
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<criteria>Acute leukemia , aggressive lymphoma , bone marrow stem cell transplantation ; Neutropenia ( &lt; 500 neutrophils/ÂµL ) least 10 day ; Newly diagnose fever ; Positive panfungal polymerase chain reaction assay Documented bacterial infection screen randomization Fungemia document invasive fungal infection screen randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Neutropenia</keyword>
	<keyword>Fever unknown origin</keyword>
	<keyword>Empirical treatment</keyword>
	<keyword>Voriconazole</keyword>
</DOC>